Company shares last traded at $2.05 which is just over the 50 day moving average of $1.90 and impressively lower than the 200 day moving average of $3.74. The 50 day moving average went up $0.15 or +7.64% whereas the 200 day moving average was down $-1.69 or -45.17%. Trading was light with 0 shares changing hands by the end of trading on Tuesday. Shares saw a steep decrease in trading volume of 100.00% under the normal average daily volume.
Investors are a little more bearish on shares of the company lately if you evaluate the change in short interest. The stock recorded a rise in short interest of 29.79% as of October 13, 2017 from the last reporting period. Short interest increased 361,198 over that timeframe. The days to cover decreased to 1.0 and the percentage of shorted shares is 0.21% as of October 13.
In the last earnings report the EPS was $-6.50 and is projected to be $-1.40 for the current year with 8,294,000 shares currently outstanding. Next quarter’s EPS is forecasted at $-0.16 and the next full year EPS is projected to be $-0.64.
EnteroMedics Inc. (EnteroMedics), launched on July 22, 2004, is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Business’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to block the vagus nerve. The Business’s initial product is the Maestro Rechargeable System, which uses VBLOC therapy to limit the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness..